Abstract | BACKGROUND: METHODS: RESULTS: At week 26, the mean increase of MCV was similar among patients treated with azathioprine alone (mean of 7.9 fL) or in combination with infliximab (mean of 8.5 fL). In the azathioprine group, 63.6% of patients with ΔMCV >7 were in steroid-free clinical remission at week 26 as compared with 33.3% of patients without ΔMCV >7 (P = 0.0046). In the combination therapy group, ΔMCV above 7 was associated with mucosal healing (75.0% for ΔMCV >7 versus 47.1% for ΔMCV <7, P = 0.0172) but not with steroid-free clinical remission. Patients with a ΔMCV above 7 were more likely to have infliximab trough level above 3 μg/mL at week 30 (68.4% versus 38.8% for ΔMCV <7, P = 0.0032). CONCLUSIONS:
|
Authors | Guillaume Bouguen, Charles Sninsky, Kezhen L Tang, Jean-Frederic Colombel, Geert DʼHaens, Asher Kornbluth, Gerassimos J Mantzaris, Daniel Rachmilewitz, Walter Reinisch, Paul Rutgeerts, Mark Molenda, C Jannekevan der Woude, William J Sandborn |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 21
Issue 3
Pg. 606-14
(Mar 2015)
ISSN: 1536-4844 [Electronic] England |
PMID | 25581826
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Gastrointestinal Agents
- Immunosuppressive Agents
- Infliximab
- Azathioprine
|
Topics |
- Adult
- Azathioprine
(therapeutic use)
- Biomarkers
(analysis)
- Crohn Disease
(drug therapy, pathology)
- Double-Blind Method
- Drug Therapy, Combination
- Erythrocyte Indices
(drug effects)
- Erythrocytes
(drug effects, pathology)
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Infliximab
(therapeutic use)
- Male
- Mucous Membrane
(drug effects, pathology)
- Prognosis
- Wound Healing
(drug effects)
|